Birdwatch Note
2023-11-01 21:30:17 UTC - MISINFORMED_OR_POTENTIALLY_MISLEADING
Fenbendazole is officially rejected for toxicity, variants and lack of human clinical trials,but preclinical in vitro studies(example: https://www.sciencedirect.com/science/article/pii/S2468294222000910)and its ability to arrest colorectal cancer(example: https://aacrjournals.org/cancerres/article/82/12_Supplement/2313/701049/Abstract-2313-Fenbendazole-induces-cell-cycle)suggest rejection is also due to costly R&D with no profit likely for such a cheap drug.
Written by FF614092EC4515405AEAB3A01A50673CFBC895CFBB1651631E7DA7A69F2D406B
Participant Details
Original Tweet
Tweet embedding is no longer reliably available, due to the platform's instability (in terms of both technology and policy). If the Tweet still exists, you can view it here: https://twitter.com/foo_bar/status/1719753740658299254
Please note, though, that you may need to have your own Twitter account to access that page. I am currently exploring options for archiving Tweet data in a post-API context.
All Information
- ID - 1719829234774864310
- noteId - 1719829234774864310
- participantId -
- noteAuthorParticipantId - FF614092EC4515405AEAB3A01A50673CFBC895CFBB1651631E7DA7A69F2D406B Participant Details
- createdAtMillis - 1698874217105
- tweetId - 1719753740658299254
- classification - MISINFORMED_OR_POTENTIALLY_MISLEADING
- believable -
- harmful -
- validationDifficulty -
- misleadingOther - 1
- misleadingFactualError - 1
- misleadingManipulatedMedia - 0
- misleadingOutdatedInformation - 0
- misleadingMissingImportantContext - 0
- misleadingUnverifiedClaimAsFact - 1
- misleadingSatire - 0
- notMisleadingOther - 0
- notMisleadingFactuallyCorrect - 0
- notMisleadingOutdatedButNotWhenWritten - 0
- notMisleadingClearlySatire - 0
- notMisleadingPersonalOpinion - 0
- trustworthySources - 1
- summary
- Fenbendazole is officially rejected for toxicity, variants and lack of human clinical trials,but preclinical in vitro studies(example: https://www.sciencedirect.com/science/article/pii/S2468294222000910)and its ability to arrest colorectal cancer(example: https://aacrjournals.org/cancerres/article/82/12_Supplement/2313/701049/Abstract-2313-Fenbendazole-induces-cell-cycle)suggest rejection is also due to costly R&D with no profit likely for such a cheap drug.
Note Status History
| createdAt | timestampMillisOfFirstNonNMRStatus | firstNonNMRStatus | timestampMillisOfCurrentStatus | currentStatus | timestampMillisOfLatestNonNMRStatus | mostRecentNonNMRStatus | participantId |
| 2023-11-01 21:30:17 UTC (1698874217105) |
1969-12-31 23:59:59 UTC (-1) |
2023-11-02 07:47:06 UTC (1698911226426) |
NEEDS_MORE_RATINGS | 1969-12-31 23:59:59 UTC (-1) |
Note Ratings
| rated at | rated by | |
| 2023-11-02 16:25:15 -0500 | Rating Details | |
| 2023-11-02 16:20:34 -0500 | Rating Details | |
| 2023-11-02 10:57:32 -0500 | Rating Details | |
| 2023-11-02 05:05:18 -0500 | Rating Details | |
| 2023-11-02 03:54:20 -0500 | Rating Details | |
| 2023-11-02 00:19:25 -0500 | Rating Details | |
| 2023-11-01 16:57:15 -0500 | Rating Details |